Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jiac.2020.12.021 http://scihub22266oqcxt.onion/10.1016/j.jiac.2020.12.021 33402301!7833994!33402301     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Infect+Chemother 2021 ; 27 (2): 390-392 Nephropedia Template TP {{tp|p=33402301|t=2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19 |pdf=|usr=}}{{33402301}} gab.com Text Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19 JO: J Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33402301 #FOAvip Favipiravir is an antiviral drug that is expected to have a therapeutic effect on SARS-CoV2 infection. Teratogenicity and hyperuricemia are known as the main side effects of favipiravir, but little is known about other side effects. This report describes a case of cholestatic liver injury induced by favipiravir. A 73-year-old Japanese with a history of alcoholic hepatitis was infected with SARS-CoV2. Drug therapy was instituted with lopinavir/ritonavir combined with interferon beta-1b. However, his condition worsened despite additional support with continuous hemodiafiltration and veno-venous extracorporeal membrane oxygenation. We suspected complications of bacterial pneumonia and started favipiravir in addition to antimicrobial therapy. Favipiravir was administered at 6000 mg/day on the first day and 2400 mg/day for the second and subsequent days for 14 days. After the initiation of antibiotics, transaminase and total bilirubin were elevated, suggesting a transient cholestasic liver dysfunction. The liver dysfunction in this case may have been triggered by antibacterial treatment, and high dose of favipiravir may have promoted the deterioration of liver function. Monitoring of liver function is vital and close attention should be paid when using favipiravir at high doses or in patients with impaired liver function. Twit Text FOAVip Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19 ????J Infect Chemother http://www.kidney.de/pget.php?&tw=1&pmid=33402301 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33402301 #FOAvip English Wikipedia <ref>{{Cite pmid|33402301}}</ref> Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19 #MMPMID33402301 Yamazaki S; Suzuki T; Sayama M; Nakada TA; Igari H; Ishii I J Infect Chemother 2021[Feb]; 27 (2): 390-392 PMID33402301show ga Favipiravir is an antiviral drug that is expected to have a therapeutic effect on SARS-CoV2 infection. Teratogenicity and hyperuricemia are known as the main side effects of favipiravir, but little is known about other side effects. This report describes a case of cholestatic liver injury induced by favipiravir. A 73-year-old Japanese with a history of alcoholic hepatitis was infected with SARS-CoV2. Drug therapy was instituted with lopinavir/ritonavir combined with interferon beta-1b. However, his condition worsened despite additional support with continuous hemodiafiltration and veno-venous extracorporeal membrane oxygenation. We suspected complications of bacterial pneumonia and started favipiravir in addition to antimicrobial therapy. Favipiravir was administered at 6000 mg/day on the first day and 2400 mg/day for the second and subsequent days for 14 days. After the initiation of antibiotics, transaminase and total bilirubin were elevated, suggesting a transient cholestasic liver dysfunction. The liver dysfunction in this case may have been triggered by antibacterial treatment, and high dose of favipiravir may have promoted the deterioration of liver function. Monitoring of liver function is vital and close attention should be paid when using favipiravir at high doses or in patients with impaired liver function. |*COVID-19 Drug Treatment[MESH] |Aged[MESH] |Amides/*adverse effects/therapeutic use[MESH] |Antiviral Agents/*adverse effects/therapeutic use[MESH] |COVID-19/complications[MESH] |Chemical and Drug Induced Liver Injury/*etiology[MESH] |Cholestasis/*etiology[MESH] |Drug Therapy, Combination[MESH] |Extracorporeal Membrane Oxygenation[MESH] |Humans[MESH] |Lopinavir/therapeutic use[MESH] |Male[MESH] |Pyrazines/*adverse effects/therapeutic use[MESH] |Ritonavir/therapeutic use[MESH]Suspected cholestatic liver injury induced by favipiravir in a patient(epmc).pdf DeepDyve Pubget Overpricing